Ordookhani Arash, Burman Kenneth D
Endocrine Section, Department of Internal Medicine, Providence Hospital, Washington, DC, 20017.
Endocrine Section, MedStar Washington Hospital Center, Washington, DC, 20010.
Int J Endocrinol Metab. 2017 Apr 23;15(3):e44157. doi: 10.5812/ijem.44157. eCollection 2017 Jul.
There are contradictory results on the effect of hyperthyroidism on hemostasis. Inadequate population-based studies limited their clinical implications, mainly on the risk of venous thromboembolism (VTE). The present review focuses on hemostatic changes in overt and subclinical hyperthyroidism.
A systematic literature search was conducted employing MEDLINE database. The following words were used for the search: Hyperthyroidism; thyrotoxicosis; Graves disease; goiter, nodular; hemostasis; blood coagulation factors; blood coagulation disorders; venous thromboembolism; bleeding; fibrinolysis. The articles that were related to hyperthyroidism and hemostasis are used in this manuscript.
Hyperthyroidism, either overt or subclinical, renders a hypercoagulable state, although there are several studies with contradictory findings in the literature. Hypercoagulability may be caused by an increase in the level of various coagulation factors such as factor (F) VIII, FX, FIX, von Willebrand F (vWF), and fibrinogen, while hypofibrinolysis by changes in coagulation parameters such as a decrease in plasmin and plasmin activator or an increase in α2-antiplasmin, plasminogen activator inhibitor-1 and thrombin activatable fibrinolysis inhibitor.
Although many reports are in favor of a hypercoagulable state in overt hyperthyroidism but this finding at the biochemical level and its clinical implication, on the occurrence of VTE, has yet to be confirmed.
关于甲状腺功能亢进对止血的影响存在相互矛盾的结果。基于人群的研究不足限制了它们的临床意义,主要是关于静脉血栓栓塞(VTE)的风险。本综述重点关注显性和亚临床甲状腺功能亢进时的止血变化。
使用MEDLINE数据库进行系统的文献检索。检索词如下:甲状腺功能亢进;甲状腺毒症;格雷夫斯病;结节性甲状腺肿;止血;血液凝固因子;血液凝固障碍;静脉血栓栓塞;出血;纤维蛋白溶解。本手稿使用了与甲状腺功能亢进和止血相关的文章。
无论显性还是亚临床甲状腺功能亢进,都会导致高凝状态,尽管文献中有几项研究结果相互矛盾。高凝状态可能由多种凝血因子水平升高引起,如因子(F)VIII、FX、FIX、血管性血友病因子(vWF)和纤维蛋白原,而纤维蛋白溶解功能减退则是由于凝血参数的变化,如纤溶酶和纤溶酶激活剂减少或α2-抗纤溶酶、纤溶酶原激活剂抑制剂-1和凝血酶激活的纤维蛋白溶解抑制剂增加。
尽管许多报告支持显性甲状腺功能亢进存在高凝状态,但这一在生化水平上的发现及其对VTE发生的临床意义尚未得到证实。